Stockscreener 앱 받기
6.25
0.64%
0.04
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Earnings call transcript: Relmada Therapeutics Q4 2025 shows EPS miss, stock stable - Investing.com
RLMD: NDV-01 delivers high response rates in NMIBC, with Phase 3 trials and strong financial runway ahead - TradingView
RLMD: NDV-01 achieved durable, high response rates with favorable safety in high-risk NMIBC - TradingView
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics 10-K: $0 Revenue, $(1.45) EPS on $(57.39)M Net Loss - TradingView
Relmada (NASDAQ: RLMD) pivots to NDV-01 cancer drug and sepranolone - Stock Titan
RLMD: Strong NDV-01 clinical results and $160M financing support Phase 3 launch and extended cash runway - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update - The Manila Times
BRIEF-Relmada Therapeutics Q4 EPS USD -0.27 - TradingView
Bladder cancer drug shows 76% response at 12 months as Relmada readies Phase 3 - Stock Titan
Lucid Capital Markets initiates coverage of Relmada Therapeutics (RLMD) with buy recommendation - MSN
Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors - TipRanks
Relmada’s Withdrawn BOOST Trial Resets Expectations for NDV-01 and RLMD - TipRanks
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD) - The Globe and Mail
Short Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Drops By 24.8% - MarketBeat
Mizuho reiterates Relmada stock rating on positive cancer trial data By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on positive cancer trial data - Investing.com
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' - StreetInsider
Relmada Therapeutics (RLMD) Projected to Post Earnings on Thursday - MarketBeat
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data - Yahoo Finance
RLMD stock surges 42% in a week: Here's what you should know - MSN
Relmada Therapeutics, Inc. announced that it has received $159.999996 million in funding from a group of investors - marketscreener.com
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
RLMD Shares Jump 42% Over the Past Week: Key Information You Need - Bitget
Relmada reports 76% response rate for bladder cancer therapy - Investing.com Nigeria
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Biotech Relmada schedules March 19 call on Q4 2025 results - Stock Titan
Should I buy Relmada Therapeutics (RLMD) - Zacks Investment Research
Relmada Therapeutics secures $160M in PIPE financing - Investing.com Nigeria
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - 富途牛牛
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap DownTime to Sell? - MarketBeat
Relmada Therapeutics at Leerink Global: Strategic Shift to Uro-Oncology By Investing.com - Investing.com Canada
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement - Yahoo Finance
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer - Indian Pharma Post
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01 - TipRanks
Relmada reports 76% response rate for bladder cancer therapy By Investing.com - Investing.com Canada
Relmada Therapeutics secures $160M in PIPE financing By Investing.com - Investing.com Canada
Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data - MEXC
Relmada CEO and CFO head to Miami for Leerink fireside chat, investor meetings - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Minichart
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN
Mizuho reiterates Relmada stock rating on bladder cancer trial data By Investing.com - Investing.com UK
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data - Intellectia AI
Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset - timothysykes.com
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - Investing News Network
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - Investing News Network
Relmada Therapeutics (RLMD) Stock Surges as Bladder Cancer Trial Shows 76% Response Rate - MEXC
Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement - Quiver Quantitative
Relmada Therapeutics, Inc. announced that it expects to receive $159.999996 million in funding from a group of investors - marketscreener.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Mizuho reiterates Relmada stock rating on bladder cancer trial data - Investing.com
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3 - Bez Kabli
1.20%
0.06%
자본화:
|
볼륨(24시간):